 |
Minimale Einzahlung $50 Exklusive Aktion |
Unser Ergebnis |
0% Kommission |
Are you looking to buy Sage Therapeutics stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:SAGE! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Sage Therapeutics stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Durchschnittliches Volumen
520,296 shs
MARKTKAPPE
$4.30 billion
Börse
NASDAQ
Kaufen Sie diese Aktie!
|
NAME
|
TICKER
|
INDUSTRIE
|
SECTOR
|
VOLUME
|
KAUFEN SIE DIESE AKTIE JETZT
|
|---|---|---|---|---|---|
|
NASDAQ:SAGE
|
Pharmazeutische Präparate
|
Medizinisch
|
5,223 shs
|
Below is a quick guide on how to buy NASDAQ:SAGE stocks safe, fast and around the world in less than five minutes.
Schritt 1: Eröffnen Sie ein Konto bei eToro – eToro is the best broker to buy Sage Therapeutics shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Schritt 2: Laden Sie Ihre ID hoch - Gemäß den KYC-Vorschriften wird eToro Sie bitten, eine Kopie Ihres Reisepasses oder Führerscheins hochzuladen.
Schritt 3: Geld einzahlen - Zahlen Sie etwas Geld auf Ihr neu eingerichtetes eToro Konto ein. Sie können zwischen Banküberweisung, E-Wallet, Debit-/Kreditkarte oder Paypal wählen.
Schritt 4: Buy Sage Therapeutics – Search for “”NASDAQ:SAGE”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Sage Therapeutics stocks with 0% commission!.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
18 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Sage Therapeutics stock.
Wall Street analysts have given Sage Therapeutics a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Sage Therapeutics wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
2 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
3 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:SAGE stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Sage Therapeutics stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Sage Therapeutics stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Da es sich bei eToro um eine regulierte Plattform handelt, müssen Sie das KYC-Verfahren abschließen. Dies ist gängige Praxis und dauert nur ein paar Minuten. Sie müssen einen Lichtbildausweis (Reisepass, Führerschein) und einen Adressnachweis (Stromrechnung, Kontoauszug) vorlegen.
Sobald Sie sich angemeldet und Ihr Konto verifiziert haben, müssen Sie Geld einzahlen. eToro akzeptiert Kredit-/Debitkarten, Banküberweisungen und auch E-Wallets. Was auch immer Sie bevorzugen, es wird etwas für Sie dabei sein.
Now that you’ve funded your eToro account, just type “NASDAQ:SAGE stocks" in die Suchleiste am oberen Rand des Bildschirms ein und drücken Sie auf "Handeln".
All that’s left is to buy some NASDAQ:SAGE stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:SAGE is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Sage Therapeutics stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Sage Therapeutics.
Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, beating the consensus estimate of ($2.30) by $0.27. The biopharmaceutical company earned $1.64 million during the quarter, compared to analysts’ expectations of $1.85 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 63.81% and a negative net margin of 7,706.84%. The business’s revenue was down 54.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.48) EPS.
View Sage Therapeutics’ earnings history.
Sage Therapeutics’ stock was trading at $42.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have increased by 96.3% and is now trading at $83.02.
18 analysts have issued 12-month price objectives for Sage Therapeutics’ shares. Their forecasts range from $28.00 to $135.00. On average, they anticipate Sage Therapeutics’ share price to reach $80.05 in the next twelve months. This suggests that the stock has a possible downside of 3.6%.
View analysts’ price targets for Sage Therapeutics or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:SAGE stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mehr als 95% der Kundengelder werden offline, in kalten Lagern, aufbewahrt, was für jeden Broker, der Ihr Vermögen verwaltet, entscheidend ist. Unabhängig davon, wie sicher eine Plattform sein soll, empfehlen wir die Verwendung von 2FA, um eine zusätzliche Sicherheitsebene für Ihr Konto zu schaffen.
eToro bietet Nutzern eine Reihe von Funktionen, um so schnell wie möglich mit dem Investieren zu beginnen. Es gibt eine relativ einzigartige Funktion namens Copy Trading, mit der Sie ein passives Einkommen erzielen können, indem Sie erfahrene Händler spiegeln. So können Sie schnell Gewinne erzielen und erhalten ein besseres Verständnis für die Strategien, die von Profis verwendet werden. Außerdem können Sie bei eToro in verwaltete Portfolios investieren. Ein verwaltetes Portfolio besteht aus einer Vielzahl ähnlicher Vermögenswerte, die in Gruppen zusammengefasst sind. Wenn Sie bereits über Handelserfahrung verfügen, können Sie auch in andere Märkte als Aktien investieren, da eToro den Handel mit ETFs, Rohstoffen, Kryptowährungen und Indizes ermöglicht. Wenn Sie bereits außerhalb des Aktienmarktes investieren, kann dies sehr nützlich sein, da Sie so alle Ihre Investitionen an einem einzigen Ort verwalten können.
Sage Therapeutics’ management team includes the following people:
Ms. Kimi E. Iguchi, CFO & Treasurer (Age 59, Pay $536.37k)
Mr. Michael Cloonan, Chief Operating Officer (Age 50, Pay $582.75k)
Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 59, Pay $564.84k)
Dr. Jeffrey M. Jonas, Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 68, Pay $983.77k)
Dr. Stephen J. Kanes, Chief Medical Officer (Age 56, Pay $580.67k)
Mr. Barry E. Greene, Pres, CEO & Director (Age 58)
Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
Dr. Albert J. Robichaud, Chief Scientific Officer (Age 60)
Mr. Matthew Calistri, VP of Investor Relations
Ms. Erin E. Lanciani, Sr. VP of People & Organizational Strategy (Age 52)
Some companies that are related to Sage Therapeutics include BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Axon Enterprise (AXON), Dr. Reddy’s Laboratories (RDY), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS) and BridgeBio Pharma (BBIO).
View all of SAGE’s competitors.
CFDs sind komplexe Instrumente und bergen aufgrund der Hebelwirkung ein hohes Risiko, schnell Geld zu verlieren. 68% der Konten von Kleinanlegern verlieren Geld beim Handel mit CFDs bei diesem Anbieter. Sie sollten sich überlegen, ob Sie verstehen, wie CFDs funktionieren und ob Sie das hohe Risiko, Ihr Geld zu verlieren, eingehen können.
Based on aggregate information from Reportlab watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).
Sage Therapeutics trades on the NASDAQ under the ticker symbol “SAGE.”
Sage Therapeutics’ stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.59%), Victory Capital Management Inc. (1.41%), Jennison Associates LLC (1.08%), First Trust Advisors LP (0.32%), Candriam Luxembourg S.C.A. (0.28%) and California Public Employees Retirement System (0.25%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for Sage Therapeutics.
SAGE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., State of New Jersey Common Pension Fund D, Pinnacle Associates Ltd., Candriam Luxembourg S.C.A., Banque Cantonale Vaudoise, Westside Investment Management Inc., and Pacer Advisors Inc..
View insider buying and selling activity for Sage Therapeutics or view top insider-selling stocks.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
SAGE stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Jennison Associates LLC, California Public Employees Retirement System, Y Intercept Hong Kong Ltd, Exchange Traded Concepts LLC, Comerica Bank, SG Americas Securities LLC, and Arthur M. Cohen & Associates LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Interaktive Makler Bewertung, eToro Überprüfung, DEGiro Rückblick, AvaTrade Bewertung, IG Markets Rückblick, IC Märkte Rückblick, CMC Markets Rückblick, Admiral Markets Rückblick und viele mehr. Lesen Sie eine der Bewertungen, um alles über den Broker zu erfahren, und beginnen Sie jetzt mit dem Kauf von Aktien.
One share of SAGE stock can currently be purchased for approximately $83.02.
Sage Therapeutics has a market capitalization of $4.32 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis.
Sage Therapeutics employs 675 workers across the globe.
The official website for Sage Therapeutics is www.sagerx.com.
Wir von Reportlab.org möchten sicherstellen, dass Sie alle wichtigen Informationen über Aktien kaufen. Wir bieten Ihnen die besten Leitfäden zum Thema Börse mit persönlichen Bewertungen, Hintergrundinformationen, Plattformbewertungen, Anleitungen und mehr. Möchten Sie weitere Informationen erhalten? Dann schauen Sie sich die OTC-Aktien, NASDAQ-Aktien, NYSE-Aktien, LON-Aktien, FRA-Aktien, ETR-Aktien, EPA-Bestände, TSX-Aktien oder Amex Aktien. Sie suchen nach detaillierteren Informationen wie 5g Vorräte, Biotech-Aktien, Goldvorräte und andere Informationen aus unserem Reportlab.
How can you buy Sage Therapeutics stock on the internet?
You can easily buy Sage Therapeutics stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Eine weitere Option ist die Nutzung eines regulierten Brokers wie IC-Märkte oder Interaktive Makler. You can an account with these brokers and start buying or trading NASDAQ:SAGE stocks in a safe and complete environment to trade in.
Where to buy Sage Therapeutics stock?
You will first want to find a licensed broker that supports NASDAQ:SAGE stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:SAGE stocks in a safe and complete environment.
Is NASDAQ:SAGE stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:SAGE stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Sage Therapeutics stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:SAGE is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Sage Therapeutics stock.
How do you trade Sage Therapeutics stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Sage Therapeutics stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:SAGE stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Sage Therapeutics stock?
To sell your NASDAQ:SAGE stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Sage Therapeutics stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:SAGE stock.
Stephen kennt sich gut mit Finanzprodukten aus und hat insbesondere eine große Leidenschaft für die Aktienmärkte und ihre Teilnehmer. Wir hoffen, dass die bereitgestellten Informationen Ihnen helfen werden. Ist Ihnen etwas nicht ganz klar? Bitte hinterlassen Sie Ihre Fragen oder Kommentare unten auf der Seite.
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ |
Newsletter
Neueste Nachrichten
| |
Unser Ergebnis |
0% Kommission |
Aktien & Krypto-Daten in Echtzeit
Benachrichtigungen, Tipps & Neuigkeiten
Beste Aktien & Krypto-Führer
Online Broker & Börse Bewertungen
Reportlab Finanzen ist eine rein informative Website und stellt in keinem Fall eine Anlageberatung dar. Alle Investitionen sind mit Risiken verbunden und Sie können Ihre gesamten Investitionen verlieren. Investieren Sie kein Geld, das Sie sich nicht leisten können, zu verlieren.
Reportlab Finanzen
38 Holburn Lane
Heckfield Green
IP21 0UB
Vereinigtes Königreich
Copyright © 2022 Reportlab.Finance | Alle Rechte vorbehalten.
